The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of neoadjuvant docetaxel (D) plus bevacizumab (B) in patients (pts) with high-risk localized prostate cancer.
W. K. Oh
Consultant or Advisory Role - Genentech; Sanofi
Research Funding - Genentech; Sanofi
M. D. Galsky
Consultant or Advisory Role - Bristol-Myers Squibb; Foundation Medicine; GlaxoSmithKline; Pfizer
Research Funding - Celera; Viator
M. Barry
No relevant relationships to disclose
F. Fennessey
No relevant relationships to disclose
J. P. Richie
No relevant relationships to disclose
J. H. Hayes
No relevant relationships to disclose
R. S. Bhatt
No relevant relationships to disclose
M. Taplin
No relevant relationships to disclose
P. G. Febbo
Honoraria - Sanofi
R. W. Ross
No relevant relationships to disclose